MDUK Oxford Neuromuscular Centre

Roche’s Evrysdi^® shows long-term efficacy in spinal muscular atrophy

16 March 2022 | By Hannah Balfour (European Pharmaceutical Review)

New data demonstrates the long-term safety and efficacy of Evrysdi® (risdiplam) in a broad population of people with spinal muscular atrophy (SMA).